INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 336 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $244,783 | -81.7% | 3,574 | -81.5% | 0.01% | -82.1% |
| Q1 2024 | $1,337,013 | -31.8% | 19,321 | -29.4% | 0.03% | -34.9% |
| Q4 2023 | $1,960,025 | +26.2% | 27,367 | -8.2% | 0.04% | +13.2% |
| Q3 2023 | $1,553,168 | -64.8% | 29,817 | -57.2% | 0.04% | -63.1% |
| Q2 2023 | $4,415,557 | -24.7% | 69,734 | -35.6% | 0.10% | -40.5% |
| Q1 2023 | $5,867,369 | -64.1% | 108,354 | -64.9% | 0.17% | -62.5% |
| Q4 2022 | $16,333,546 | +8.5% | 308,646 | -4.6% | 0.46% | +4.1% |
| Q3 2022 | $15,058,000 | +4.1% | 323,609 | +27.7% | 0.44% | +9.4% |
| Q2 2022 | $14,459,000 | -2.1% | 253,319 | +5.0% | 0.40% | +16.0% |
| Q1 2022 | $14,762,000 | +37.7% | 241,255 | +17.8% | 0.35% | +54.4% |
| Q4 2021 | $10,720,000 | +192.3% | 204,822 | +108.2% | 0.23% | +175.6% |
| Q3 2021 | $3,667,000 | – | 98,356 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |